Satellos Announced the Start of Phase 2A (BASECAMP) Study of SAT-3247 in Ambulatory Patients with Duchenne
Satellos announced the commencement of a Phase 2A trial of SAT-3247 (NCT07287189) in ambulatory patients with Duchenne aged 7 to 10 years. In this...
China-Based Ractigen Therapeutics is Initiating Clinical Trials to Investigate The Safety and Tolerability of RAG-18 in Patients with DMD
According to Ractigen Therapeutics, this study is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerance, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary...
Ractigen Therapeutics Doses First Patient in IIT Study of RAG-18, a Potential Game-Changing saRNA Therapeutic for Duchenne Muscular Dystrophy
Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, today announced the successful dosing of the first patient in its investigator-initiated trial...
Del-Zota Clinical Trial Begins in the US in Participants with DMD Mutations Amenable to Exon 44 Skipping
Avidity Biosciences announced the commencement of clinical trials to provide access to delpacibart zotadirsen (AOC 1044) to eligible patients diagnosed with DMD mutations...
Researchers Develop Optimized Smad7 Gene Therapy to Target Duchenne Muscular Dystrophy
On November 25, 2025, researchers Buel D. Rodgers and Christopher W. Ward published a groundbreaking study in Gene Therapy that unveiled a codon-optimized human...